Artículos de revistas
SK-HEP cells and lentiviral vector for production of human recombinant factor VIII
Date
2012Registration in:
BIOTECHNOLOGY LETTERS, DORDRECHT, v. 34, n. 8, pp. 1435-1443, AUG, 2012
0141-5492
10.1007/s10529-012-0925-4
Author
Rosa, Nathalia Gonsales da
Swiech, Kamilla
Picanco-Castro, Virginia
Russo-Carbolante, Elisa Maria de Sousa
Soares Neto, Mario Abreu
Castilho-Fernandes, Andrielle de
Faca, Vitor Marcel
Fontes, Aparecida Maria
Covas, Dimas Tadeu
Institutions
Abstract
Hemophilia A is caused by a deficiency in coagulation factor VIII. Recombinant factor VIII can be used as an alternative although it is unavailable for most patients. Here, we describe the production of a human recombinant B-domain-deleted FVIII (rBDDFVIII) by the human cell line SK-HEP-1, modified by a lentiviral vector rBDDFVIII was produced by recombinant SK-HEP cells (rSK-HEP) at 1.5-2.1 IU/10(6) in 24 h. The recombinant factor had increased in vitro stability when compared to commercial pdFVIII. The functionality of rBDDFVIII was shown by its biological activity and by tail-clip challenge in hemophilia A mice. The rSK-HEP cells grew in a scalable system and produced active rBDDFVIII, indicating that this platform production can be optimized to meet the commercial production scale needs.